May 2019 FDA Recall Promacta by Novartis Pharmaceuticals Corp.
D-1309-2019 - Cross Contamination with Other Products

This Class I drug recall was voluntarily initiated by Novartis Pharmaceuticals Corp. on May 11, 2019 for the product Promacta. The FDA reported the reason for recall as cross contamination with other products. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1309-2019

Reason for Recall
Cross Contamination with Other Products: product is being recalled due to possible cross-contamination with peanut flour.
Initiated
05-11-2019
Reported
05-29-2019
Quantity
792 cartons

Recall Profile & Regulatory Data

Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Novartis Pharmaceuticals Corp.
Nationwide with in the United States
Promacta (eltrombopag) 12.5 mg for Oral Suspension, Rx Only Manufactured by: Halo Pharmaceuticals, Inc. Whippany, New Jersey 07981 Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936 Product of Ireland, NDC 0078-0972-61.

Batch or Lot Expiration Information

Lot# : 8H57901589, Exp. 09/2020; 9H57900189 and 9H57900289, Exp. 12/2020.